# Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

> **NCT03367819** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 44 (actual)

## Conditions studied

- Prostate Cancer
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Isatuximab SAR650984
- **DRUG:** Cemiplimab REGN2810

## Key facts

- **NCT ID:** NCT03367819
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-04
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** The study was stopped after interim analysis indicated that overall result was not sufficient to satisfy per-protocol criteria to move forward in metastatic, castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) cohorts.
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367819, "Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03367819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*